These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16337857)

  • 1. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L; Levan K; Partheen K; Helou K; Horvath G
    Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
    Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of drug resistance in human ovarian carcinoma studied by comparative genomic hybridization].
    Ying HC; Zhang SL; Jiang T; Ouyang L; Lü J
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1009-12. PubMed ID: 17672960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
    Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
    Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
    Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
    Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
    Partheen K; Levan K; Osterberg L; Helou K; Horvath G
    Genes Chromosomes Cancer; 2004 Aug; 40(4):342-8. PubMed ID: 15188458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
    Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
    Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors.
    Helou K; Padilla-Nash H; Wangsa D; Karlsson E; Osterberg L; Karlsson P; Ried T; Knutsen T
    Cancer Genet Cytogenet; 2006 Oct; 170(1):1-8. PubMed ID: 16965948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
    Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
    Agarwal R; Kaye SB
    Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy in epithelial ovarian cancer.
    Caldas C; Morris LE; McGuire WP
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):179-94. PubMed ID: 8015763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.
    Takano M; Fujii K; Kita T; Kikuchi Y; Uchida K
    Oncol Rep; 2004 Dec; 12(6):1177-82. PubMed ID: 15547734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.